Fiche publication
Date publication
février 2026
Journal
Neurology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BIRCK Catherine
Tous les auteurs :
Kumar R, Gravett S, Jelic V, Lange J, Oftedal L, Ciullini A, Bacınoğlu MB, De Luca CMG, Hamied L, Birck C, Blanc F, Hoede PL, Lemstra AW, Gonzalez MC, Aarsland D, Teunissen CE, Bousiges O, Moda F, Maple-Grødem J, Abelein A, Ferreira D
Lien Pubmed
Résumé
The α-synuclein (α-syn) seed amplification assay (SAA) has shown promising results for diagnosing dementia with Lewy bodies (DLB) using CSF samples. A barrier to implementing α-syn SAA clinically is the use of different protocols for the assay. It is unknown how different protocols perform in comparison with each other. We compared the performance of α-syn SAA across 4 laboratories using CSF samples of patients with DLB.
Mots clés
Humans, Lewy Body Disease, cerebrospinal fluid, alpha-Synuclein, cerebrospinal fluid, Male, Female, Aged, Cross-Sectional Studies, Retrospective Studies, Middle Aged, Laboratories, standards, Sensitivity and Specificity, Amyloid beta-Peptides, cerebrospinal fluid, Biomarkers, cerebrospinal fluid, Aged, 80 and over
Référence
Neurology. 2026 02 24;106(4):e214614
